Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc.（SYRE）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · SYRE · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
44
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Spyre Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
SYRE 季度内部人买卖趋势
SYRE 内幕交易卖出 · SYRE 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · SYRE CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
SYRE 高管卖出股份 · SYRE 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 3, 2026 | Sloan Sheldon Chief Medical Officer | Option | 8,333 | $229K | Form 4 |
| Jun 3, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 8,333 | $625K | Form 4 |
| Jun 1, 2026 | Turtle Cameron CEO · Director | Sale | 3,557 | $247K | Form 4 |
| Jun 1, 2026 | Turtle Cameron CEO · Director | Sale | 8,149 | $575K | Form 4 |
| Jun 1, 2026 | Turtle Cameron CEO · Director | Sale | 3,294 | $235K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Option | 7,500 | $109K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Sale | 1,801 | $126K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Sale | 2,599 | $184K | Form 4 |
| Jun 1, 2026 | Burrows Scott L CFO | Sale | 3,100 | $223K | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 2,404 | $174K | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 33,513 | $2.47M⚡ | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 24,814 | $1.86M⚡ | Form 4 |
| May 8, 2026 | HENDERSON MICHAEL THOMAS Director | Sale | 19,269 | $1.45M⚡ | Form 4 |
| May 1, 2026 | Burrows Scott L CFO | Option | 12,500 | $181K | Form 4 |
| May 1, 2026 | Burrows Scott L CFO | Sale | 12,500 | $892K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Option | 78,333 | $2.15M⚡ | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 21,306 | $1.48M⚡ | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 19,656 | $1.39M⚡ | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 8,777 | $628K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 12,777 | $932K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 10,358 | $764K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 5,059 | $377K | Form 4 |
| May 1, 2026 | Sloan Sheldon Chief Medical Officer | Sale | 400 | $30K | Form 4 |
| May 1, 2026 | Turtle Cameron CEO · Director | Sale | 5,300 | $369K | Form 4 |
| May 1, 2026 | Turtle Cameron CEO · Director | Sale | 3,600 | $255K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 SYRE 内幕交易
SYRE 内幕交易
Spyre Therapeutics, Inc.（SYRE）内幕交易数据来源于公司内部人（包括Turtle Cameron (CEO · Director), Burrows Scott L (CFO), Sloan Sheldon (Chief Medical Officer)）提交的SEC Form 4申报文件。过去12个月内，4位内部人向SEC提交了交易申报。SYRE内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Spyre Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
SYRE 内幕交易 · 5个问题Spyre Therapeutics, Inc.（SYRE）的内部人包括高管和董事，如Turtle Cameron (CEO · Director), Burrows Scott L (CFO), Sloan Sheldon (Chief Medical Officer)等。过去12个月内，4位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026